Evidence mapPaperPMID 41637041Full record

ReviewApplied biochemistry and biotechnology2026

Transferosomes as Advanced Nanocarriers for Enhanced Drug Delivery in Skin Cancer Therapy: A Comprehensive Review.

Kateryna Mykhailivna Doroshenko, Oleksandr Noval Shevchenko

Abstract readReview
PubMed Publisher
In one paragraph

Review in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kateryna Mykhailivna DoroshenkoDepartment of Chemistry, Taras Shevchenko National University of Kyiv, Kyiv, 01601, Ukraine.
Oleksandr Noval ShevchenkoDepartment of Chemistry, Taras Shevchenko National University of Kyiv, Kyiv, 01601, Ukraine. oleksaivashev@outlook.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin cancer is one of the most prevalent malignancies worldwide, posing significant challenges to effective treatment due to limited drug penetration, systemic toxicity, and patient non-compliance. Transferosomes, a class of ultra-deformable vesicular carriers, have emerged as a promising strategy to overcome the skin barrier and improve topical and transdermal drug delivery. This review discusses the structural composition, preparation techniques, and physicochemical properties of transferosomes, emphasizing their unique mechanism of skin penetration. We summarize current research on transferosome-based formulations for delivering chemotherapeutics, photosensitizers, and natural bioactives targeting various skin cancers, including melanoma, basal cell carcinoma, and squamous cell carcinoma. Comparative analyses highlight the advantages of transferosomes over conventional vesicular systems such as liposomes and niosomes, including improved skin permeability, enhanced drug retention, and reduced systemic toxicity. Preclinical and limited clinical studies demonstrate their potential in achieving localized and sustained anticancer effects. Challenges related to formulation stability, large-scale production, and clinical translation are discussed, along with emerging approaches such as ligand functionalization and microneedle-assisted delivery. Collectively, transferosomes represent a versatile and effective nanocarrier system that holds great promise for improving the therapeutic outcomes of skin cancer treatment.

Indexed as

Antineoplastic AgentsDrug CarriersDrug Delivery SystemsNanoparticlesSkin NeoplasmsAdministration, CutaneousAnimalsHumansLiposomesMicroneedle Drug DeliveryAntineoplastic AgentsDrug CarriersLiposomesDrug encapsulationNanocarriersSkin cancerSkin penetrationTargeted therapyTransdermal deliveryTransferosomes

Identifiers

PMID41637041

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.